Q3 2018 13F Holders as of 9/30/2018
-
Type / Class
-
Equity / Common Stock, $0.00001 par value per share
-
Shares outstanding
-
166M
-
Number of holders
-
117
-
Total 13F shares, excl. options
-
37.7M
-
Shares change
-
+5.42M
-
Total reported value, excl. options
-
$697M
-
Value change
-
+$95.6M
-
Put/Call ratio
-
0.65
-
Number of buys
-
69
-
Number of sells
-
-59
-
Price
-
$18.50
Significant Holders of CytomX Therapeutics, Inc. - Common Stock, $0.00001 par value per share (CTMX) as of Q3 2018
152 filings reported holding CTMX - CytomX Therapeutics, Inc. - Common Stock, $0.00001 par value per share as of Q3 2018.
CytomX Therapeutics, Inc. - Common Stock, $0.00001 par value per share (CTMX) has 117 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 37.7M shares
of 166M outstanding shares and own 22.77% of the company stock.
Largest 10 shareholders include FMR LLC (6.74M shares), PRICE T ROWE ASSOCIATES INC /MD/ (4.09M shares), BlackRock Inc. (3.87M shares), PERCEPTIVE ADVISORS LLC (2.66M shares), Vanguard Group Inc (2.5M shares), STATE STREET CORP (1.98M shares), RENAISSANCE TECHNOLOGIES LLC (1.52M shares), Point72 Asset Management, L.P. (1.33M shares), VICTORY CAPITAL MANAGEMENT INC (890K shares), and DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) (730K shares).
This table shows the top 117 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.